2013
A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients.
Amaravadi R, Senzer N, Martin L, Schilder R, LoRusso P, Papadopoulos K, Weng D, Graham M, Adjei A. A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. Journal Of Clinical Oncology 2013, 31: 2504-2504. DOI: 10.1200/jco.2013.31.15_suppl.2504.Peer-Reviewed Original ResearchCarboplatin/paclitaxelDose-limiting toxicityLiposomal doxorubicinMultiple chemotherapyDose escalationClinical benefitExcellent tolerabilityClinical activityClinical studiesRefractory solid tumorsPhase 1 studySolid tumor patientsFurther clinical studiesAnti-tumor synergyHighest dose levelNotable clinical activityApoptotic pathway activationG regimenStable diseaseStandard dosingProgressive diseasePartial responseBell's palsyTolerable combinationReversible toxicity
2005
A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer
Lorusso P, Krishnamurthi S, Rinehart J, Nabell L, Croghan G, Varterasian M, Sadis S, Menon S, Leopold J, Meyer M. A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. Journal Of Clinical Oncology 2005, 23: 3011-3011. DOI: 10.1200/jco.2005.23.16_suppl.3011.Peer-Reviewed Original Research